RKDA — Arcadia Biosciences, Inc.

Summary of Arcadia Biosciences, Inc. Q1 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: Approximately $1.2 million, a 22% increase year-over-year.
• Zola Coconut Water Revenue: Grew 90% year-over-year, driven by a 70% increase in distribution.
• Gross Margin: 43%, down from 52% in Q1 2024; however, this marks the ninth consecutive quarter with gross margins above 30%.
• Operating Expenses: Reduced by 16% year-over-year, totaling $1.7 million, including nearly $500,000 in transaction-related fees.
• Cash Position: Ended Q1 with $3.2 million in cash, down from $4.2 million at the start of the year.
• Inventory: Increased to $1.3 million from $900,000, reflecting growth in Zola revenues and preparations for the spring-summer selling season.

2. Strategic Updates and Business Highlights

• Zola Performance: Strong sales momentum with significant distribution gains, outperforming the coconut water category, which grew 24%.
• Product Innovation: New flavors (lime and pineapple) have been well-received, with pineapple sales exceeding last year's total in the first four months of 2025.
• Intellectual Property Monetization: Completed a transaction with BioSeries, regaining rights to certain patents and receiving $750,000 in cash, which helped eliminate a $1 million contingent liability.
• Business Combination with Roosevelt Resources: The merger is progressing, with expectations to close by mid-August 2025, providing greater ownership certainty for Arcadia shareholders.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipated continued growth driven by Zola, with new customer accounts expected to impact 2025 financials.
• Tariff Impact: Management believes that the recently implemented 10% tariff will have minimal impact on Q2 results, with identified cost-saving opportunities to offset potential increases.
• Operational Efficiency: Continued focus on reducing operating expenses and cash consumption while ramping up for the busy beverage season.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Decline: The decrease in gross margin from the previous year raises concerns about cost management as the company transitions to a single product line.
• Legacy Business Exit: While progress has been made, the remaining tomato patent still represents a contingent liability, and its future commercialization remains uncertain.
• Market Competition: The coconut water market is competitive, and sustaining growth will require ongoing innovation and effective distribution strategies.

5. Notable Q&A Insights

• Distribution Pipeline: Management indicated that the potential for expanding distribution accounts is significant, with about half of the current distribution base (approximately 3,500 stores) being targeted for new opportunities.
• Timing of New Accounts: New customer accounts may take time to reflect in financial results, with a typical lag of a couple of months before products hit shelves.
• Legacy Patent Value: The remaining tomato patent has potential commercial value, but it is licensed to a third party, and there are no immediate plans for Arcadia to capitalize on it.

Overall, Arcadia Biosciences reported strong revenue growth driven by Zola, made significant strides in monetizing its intellectual property, and is positioned for continued growth despite some challenges related to gross margins and legacy liabilities.